Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/threonine kinase CK2

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Leukemia

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1038/sj.leu.2404460PMID 17082777
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multiple myeloma cell survival relies on high activity of protein kinase CK2.

  2006cited by this paper
• Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells.

  2006cited by this paper
• Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia

  2005cited by this paper
• Pharmacogenetics of folate-related drug targets in cancer treatment.

  2005cited by this paper
• Protein kinase CKIIa interacts with the Bcr moiety of Bcr/Abl and mediates proliferation of Bcr/Abl-expressing cells

  2004cited by this paper
• 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2.

  2004cited by this paper
• Mechanisms of Resistance to STI571 (Imatinib) in Philadelphia-chromosome Positive Acute Lymphoblastic Leukemia

  2004cited by this paper
• Chronic Myeloid Leukemia : Biology and Treatment

  2003cited by this paper
• Protein kinase CKIIα interacts with the Bcr moiety of Bcr/Abl and mediates proliferation of Bcr/Abl-expressing cells

  2003cited by this paper
• Down-regulation of thiamine transporter THTR2 gene expression in breast cancer and its association with resistance to apoptosis.

  2003cited by this paper
• Protein kinase CK2 signal in neoplasia.

  2001cited by this paper
• Methotrexate transport and resistance.

  1998cited by this paper

• CK2 Inhibitors Targeting Inside and Outside the Catalytic Box

  2024cites this paper
• Synthesis and evaluation of anticancer activity of new 4,5,6,7-tetrabromo-1H-benzimidazole derivatives.

  2024cites this paper
• Antitumor activity of the protein kinase inhibitor 1-(β-D-2′-deoxyribofuranosyl)-4,5,6,7-tetrabromo- 1H-benzimidazole in breast cancer cell lines

  2022cites this paper
• Inhibiting CK2 among Promising Therapeutic Strategies for Gliomas and Several Other Neoplasms

  2022cites this paper
• The Immune Regulatory Role of Protein Kinase CK2 and Its Implications for Treatment of Cancer

  2021cites this paper
• Downfalls of Chemical Probes Acting at the Kinase ATP-Site: CK2 as a Case Study

  2021cites this paper
• Protein kinase CK2: a potential therapeutic target for diverse human diseases

  2021cites this paper
• Inhibition of casein kinase 2 induces cell death in tyrosine kinase inhibitor resistant chronic myelogenous leukemia cells

  2021cites this paper
• Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia

  2019cites this paper
• In vitro effect of curcumin in combination with chemotherapy drugs in Ph+ acute lymphoblastic leukemia cells.

  2019cites this paper
• Therapeutic targeting of CK2 in acute and chronic leukemias

  2017cites this paper
• Constitutive Phosphorylation of STAT3 by the CK2–BLNK–CD5 Complex

  2017cites this paper
• Casein Kinase II (CK2), Glycogen Synthase Kinase-3 (GSK-3) and Ikaros mediated regulation of leukemia.

  2017cites this paper
• Targeting CK2-driven non-oncogene addiction in B-cell tumors

  2016cites this paper
• Protéine-kinases et cancer du rein : Découverte et validation d’une nouvelle combinaison d’inhibiteurs ciblant les protéine-kinases ATM et CK2

  2016cites this paper
• Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies.

  2016cites this paper
• The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies

  2015cites this paper
• Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias

  2015cites this paper
• Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.

  2015cites this paper
• Structure-Based Design of Protein Kinase Inhibitors

  2015cites this paper
• The Rational Design and Evaluation of CK2alpha Mutants Bearing Inhibitor-Refractory Amino Acid Substitutions

  2015influential citation
• BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation

  2015cites this paper
• Effects of different CK2 inhbition strategies in tumor cells

  2014cites this paper
• Structure-based Design of Drugs and Other Bioactive Molecules: Tools and Strategies

  2014cites this paper
• Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling

  2014cites this paper
• Diversity-oriented synthesis of pyrazolo[4,3-b]indoles by gold-catalysed three-component annulation: application to the development of a new class of CK2 inhibitors.

  2013cites this paper
• Protein Kinase CK2 in Normal and Malignant Hematopoiesis

  2013cites this paper
• The Interactome of Protein Kinase CK2

  2013cites this paper
• Aberrant signalling by protein kinase CK2 in imatinib‐resistant chronic myeloid leukaemia cells: Biochemical evidence and therapeutic perspectives

  2013cites this paper
• Addiction of Cancer Cells to CK2: Survival at All Costs or Achilles' Heel?

  2013cites this paper
• Synergistic anti-leukemic effects of CK2 inhibitors and pentabromobenzylisothioureas in vitro.

  2013cites this paper
• Casein Kinase 2α Regulates Multidrug Resistance-Associated Protein 1 Function via Phosphorylation of Thr249

  2012cites this paper
• Expression of cassini, a murine gamma-satellite sequence conserved in evolution, is regulated in normal and malignant hematopoietic cells

  2012cites this paper
• Structure-based design of novel potent protein kinase CK2 (CK2) inhibitors with phenyl-azole scaffolds.

  2012cites this paper
• Effects of the CK2 Inhibitors CX-4945 and CX-5011 on Drug-Resistant Cells

  2012cites this paper
• Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways

  2012cites this paper
• Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia

  2012cites this paper
• Serine-Threonine Protein Kinases CK1, CK2 and GSK3 in Normal and Malignant Haematopoiesis

  2011cites this paper
• The impact of PTEN regulation by CK2 on PI3K-dependent signaling and leukemia cell survival.

  2011cites this paper
• Cardiac Calsequestrin Phosphorylation And Trafficking In The Mammalian Cardiomyocyte

  2011cites this paper
• A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway.

  2011cites this paper
• Addiction to protein kinase CK2: a common denominator of diverse cancer cells?

  2010cites this paper
• Emergence of protein kinase CK2 as a key target in cancer therapy

  2010cites this paper
• Anti-neoplastic effect of protein kinase CK2 inhibitor, 2-dimethylamino-4,5,6,7-tetrabromobenzimidazole (DMAT), on growth and hormonal activity of human adrenocortical carcinoma cell line (H295R) in vitro

  2010cites this paper
• A CK2-DE PENDENT MECHANISM FOR ACTIVATION OF THE JAK-STAT SIGNALING PATHWAY: IMPLICATIONS FOR CANCER BIOLOGY

  2010cites this paper
• Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia

  2010cites this paper
• Synthesis and proapoptotic properties of new casein kinase II inhibitors.

  2010cites this paper
• Efficacy and mechanism of anti-tumor action of new potential CK2 inhibitors toward glioblastoma cells.

  2009cites this paper
• Protein Kinase CK2 in Health and Disease

  2009cites this paper
• Synthesis of new analogs of benzotriazole, benzimidazole and phthalimide--potential inhibitors of human protein kinase CK2.

  2009cites this paper
• C6‐Unsubstituted Pyrazolo[3,4‐d]pyrimidines Are Dual Src/Abl Inhibitors Effective against Imatinib Mesylate Resistant Chronic Myeloid Leukemia Cell Lines

  2009cites this paper
• New inhibitors of protein kinase CK2, analogues of benzimidazole and benzotriazole

  2008cites this paper
• A structural insight into CK2 inhibition

  2008cites this paper
• Mass spectrometry analysis of a protein kinase CK2beta subunit interactome isolated from mouse brain by affinity chromatography.

  2008cites this paper
• NF-κB in carcinoma therapy and prevention

  2008cites this paper
• Protein kinase CK2--a key suppressor of apoptosis.

  2008cites this paper
• NF-kappaB in carcinoma therapy and prevention.

  2008cites this paper
• Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2.

  2008cites this paper
• The selectivity of inhibitors of protein kinase CK2: an update.

  2008cites this paper
• Protein kinase CK2 as a druggable target.

  2008cites this paper
• Inhibition of protein kinase CK2 suppresses angiogenesis and hematopoietic stem cell recruitment to retinal neovascularization sites

  2008cites this paper
• O 1 Evaluation of 4 , 5 , 6 , 7-tetrahalogeno-1 H-isoindole-1 , 3 – diones as inhibitors of human protein kinase CK 2

  2007cites this paper
• The ATP‐Binding Site of Protein Kinase CK2 Holds a Positive Electrostatic Area and Conserved Water Molecules

  2007cites this paper
• Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia

  2007cites this paper